asco 2013: nivolumab blocking pd1 in lung cancer and melanoma
Published 11 years ago • 3.4K plays • Length 6:24Download video MP4
Download video MP3
Similar videos
-
5:31
asco 2013: pdl1 inhibitors in melanoma
-
5:03
anti-pd-1 drug nivolumab shows high and durable clinical activity in advanced melanoma
-
5:49
nivolumab extends survival for patients with the most common lung cancer
-
7:22
pd-1 inhibition in lung cancer
-
1:52
comment: pd-1 targeting mk-3475 gives long-term responses in melanoma
-
1:15
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
8:01
fda activity for nivolumab, t-vec in melanoma, new lung cancer findings, mds findings, and more
-
5:39
nivolumab plus ipilimumab in advanced melanoma
-
7:41
nivolumab potentially superior to standard chemo in advanced melanoma
-
1:20
pixatimod and nivolumab in metastatic melanoma, nsclc and mss crc
-
2:37
comment: nivolumab-based treatment halts melanoma progression
-
0:53
dr. mario sznol describes nivolumab in advanced melanoma
-
9:00
nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
-
1:17
dr. schuchter describes two trials looking at nivolumab in melanoma
-
4:30
five-year follow-up of nivolumab in nsclc
-
8:29
asco 2015: nivolumab extends survival for patients with the most common lung cancer
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
2:03
integrated genomic correlates of response to pd-1 inhibitor nivolumab in mrcc